Photocure ASA: Transactions made under share buyback program

05 Jan 2025 08:47 CET

Oslo, 5 January 2025: Reference is made to the stock exchange announcement made
by Photocure ASA ("Photocure" or the "Company") on 19 December 2024 of the
launch of Photocure's program to repurchase up to 300,000 of its own shares for
a total maximum amount of NOK 30 million during the period from 19 December
2024, until no later than 31 March 2025, pursuant to an agreement with DNB
Markets.

For the period from and including 19 December 2024, through 3 January 2024, the
Company purchased a total of 150,802 shares at an average price of NOK 62.43 per
share, all purchased as ordinary market purchases on Euronext Oslo Børs. Please
find below the transaction overview:

Date Aggregated daily Weighted average Total daily
volume (#shares) share price per day transaction value
(NOK) (NOK)
19.12.2024 23,776 61.43 1,460,610
20.12.2024 21,764 62.95 1,370,150
23.12.2024 21,170 64.17 1,358,511
27.12.2024 16,547 64.29 1,063,742
30.12.2024 21,564 63.50 1,369,286
02.02.2025 22,401 61.77 1,383,629
03.01.2025 23,580 59.73 1,408,325

Total for #shares Weighted average Total transaction
the period share price (NOK value (NOK)
150,802 62.43 9,414,253

No previously disclosed buybacks under the program.

Accumulated under #shares Weighted average Total transaction value (NOK)
the buyback share price (NOK
program
150,802 62.43 9,414,253

The issuer's holding of own shares:
Following the completion of the above transactions, Photocure owns a total of
165,924 of own shares (including 15,122 shares owned prior to the launch of the
buyback program), corresponding to 0.61% of Photocure's share capital.

Appendix:
An overview of all transactions made under the buyback program that have been
carried out during the above-mentioned time period is attached to this report
and available at www.newsweb.no.

For further information, please contact:

Erik Dahl
CFO
Photocure ASA
Tel: +4745055000
Email: ed@photocure.com

About Photocure ASA
Photocure: The Bladder Cancer Company delivers transformative solutions to
improve the lives of bladder cancer patients. Our unique technology, making
cancer cells glow bright pink, has led to better health outcomes for patients
worldwide. Photocure is headquartered in Oslo, Norway, and listed on the Oslo
Stock Exchange (OSE: PHO). For more information, please visit us at
www.photocure.com and www.cysview.com. All trademarks mentioned in this release
are protected by law and are registered trademarks of Photocure ASA.

All trademarks mentioned in this release are protected by law and are registered
trademarks of Photocure ASA.

This information is made public by Photocure ASA pursuant to the EU Market Abuse
Regulation and subject to the disclosure requirements pursuant to Section 5-12
of the Norwegian Securities Trading Act.

More information:
Access the news on Oslo Bors NewsWeb site

635947_Release.pdf
635947_Photocure_ASA_buyback_trade_details_191224_030125.pdf